Replacing David Goodlett, who accepted a faculty position at the University of Washington, Mark Wingerd, a former proteomics researcher at Pacific Northwest National Lab, joins the Institute for Systems Biology as director of the proteomics facility.
Eric Neumann moves from Beyond Genomics to Aventis, where he will serve as global head of knowledge management at the company’s Bridgewater, NJ, research facility.
Christian Marcazzo takes over as VP for business development at InforSense, a spin-out of Imperial College London.
Genomics Collaborative appoints Rick Episcopo as president and John Boyce as senior director of business development. Both men most recently worked at Sequenom.
Zisi Fotev joins RNAi research services company Cenix BioScience as chief business officer. Previously, Fotev served as vice president of business development at Atugen.
Unexpectedly, Marvin Cassman leaves his position as director of the Institue for Bioengineering, Biotechnology, and Quantitative Biomedical Research (QB3) just before the new year. Berkeley chemistry researcher Grahman Fleming will serve as an interim replacement for Cassman, a former NIGMS director who was appointed head of QB3 in 2002.
Succeeding Richard Archer, Andy Morffew takes the reins at The Automation Partnership as CEO. Prior to joining TAP, Morffew served as president of the consulting group at Paraxel, a contract research organization to the pharmaceutical industry.
Scott Patterson returns to Amgen as director for early development after an 11-month-long stint at Farmal Biomedicines, which has shut down its Pasadena, Calif., facility.
Bruker Daltonics hires Gary Kruppa as VP of western US operations, a move that will return Kruppa to the Bruker fold after a three-year hiatus as a member of the technical staff at Sandia National Laboratories.
Noel Doheny joins Qiagen as vice president of solutions for molecular diagnostics, a position based in Germantown, Md. Doheny most recently worked at ThermoBioStar.
Frank Karbe leaves his position as vice president in the health care group at Goldman Sachs to join Exelixis as senior vice president and chief financial officer.
Genome British Columbia appoints Donald Riddle chief scientific officer of the Vancouver-based research organization. Riddle joins Genome BC from the University of Missouri, Columbia, where he served as director of the molecular biology program.
Replacing Terry Sivesind, Russell Smestad takes over as president of Mirus, a gene therapy and RNA interference research company. Smestad most recently served as vice president of corporate development at PowderJect Vaccines.
Mary Taylor, a former vice president for North American regulatory affairs at Bayer, joins CuraGen as vice president of regulatory affairs.
The Translational Genomics Research Institute hires MaryAnn Guerra as vice president of research operations. Guerra joins TGen from the Matthews Media Group.
Ciphergen promotes Martin Verhoef to president of the company’s new biosystems division. Previously, Verhoef served as senior vice president for sales, marketing, and operations.
Elizabeth Hutt, formerly vice president of sales and service with Tripos, joins NuGene Technologies as vice president of sales and service. NuGene also hires Anne Kopf-Sill as the company’s new vice president of product development, and John Todd as vice president of marketing.
With the return of co-founder Stefan Stahl to academia, Lars Abrahmsen assumes the position of chief scientific officer of Uppsala, Sweden-based Affibody. Abrahmsen had previously served as senior project team leader at Biovitrum.